Sam M
Male Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male Contraceptive
Male Contraceptive Initiative (MCI), a 501(c)(3) non-profit, has partnered with the pharmaceutical company Eppin Pharma to provide a Program Related Investment (PRI) of up to $800,000 to support clinical trial activities for the company's novel short-term, non-hormonal oral male contraceptive pill.
This is the latest PRI from Male Contraceptive Initiative and represents the organization's continued evolution as it seeks to expand its support of the male contraception research and development community. "We are very excited about adding additional program related investments to our portfolio as a means of accelerating male contraceptive product development through a collaborative, 'team science' approach. Returns on these investments will go directly back into supporting research efforts to continue driving the field of non-hormonal male contraception forward," said MCI Executive Director Heather Vahdat. "Eppin Pharma is a particularly exciting investment opportunity as they have been integral at advancing the non-hormonal male contraceptive field in an effort to revolutionize family planning by providing reproductive equity to men who still have to rely on only two methods of birth control: condoms and vasectomy," Ms. Vahdat added.
Eppin Pharma's lead male contraceptive candidate is a small organic compound that binds to EPPIN, a protein on the surface of human sperm, resulting in the loss of the sperm's ability to properly function. The non-hormonal treatment Eppin Pharma is developing is intended to be fast-acting and does not affect the production of sperm.
MCI's investment in Eppin Pharma will be used to establish proof-of-concept of safety and feasibility of their contraceptive method as they prepare for human clinical trials. This is an important first step prior to conducting a larger efficacy study required for gaining regulatory approval and widespread consumer access to the therapeutic.
"We have been excited about Eppin's work since 2019, when we provided them with an initial grant to advance their work. Given the success of their science to date, we are pleased to expand our collaboration as Eppin Pharma represents the forefront of pharmacologic, non-hormonal male contraceptive methods," said MCI Research Director Dr. Logan Nickels.
"We are grateful to MCI for their dedication to supporting innovation in male contraception and for recognizing the transformative potential of our work," said Dr. Michael O'Rand, Eppin Pharma's President & Chief Executive Officer. "At Eppin Pharma, we are dedicated to developing new options for men who desire to take control of their fertility and we look forward to advancing our method to clinical trials in the near future," added Dr. O'Rand.
With over $10 million invested in product development, MCI seeks to advance male contraceptive research projects to market in order to achieve its organizational vision of "Reproductive Autonomy for All". MCI's mission is, "To empower men, and couples, to fully contribute to family planning goals by providing them the resources they need for reproductive autonomy."
Contact Information:
Kevin Shane
Communications & Design Director
[email protected]
5853072270
Press Release Service by Newswire.com
Original Source: Male Contraceptive Initiative Invests in Eppin Pharma to Support Clinical Trials for a Non-Hormonal Male Contraceptive
Wazoku Launches New Employee Insights Product: Mindpool SME
PlugXR Releases Version 5.0 at the World Economic Forum 2023, in Davos.
Market Logic Software to Launch First Generative AI Solution for Consumer Insights
BERLIN - January 19, 2023 - (Newswire.com)
Market Logic Software, the global leader for insights management solutions, has announced the development of a new portfolio of Artificial Intelligence for Consumer Insights (AICI) products tailored to serve enterprise market research and consumer insights teams.
The first product in the portfolio, to be launched in Q2 2023, will pioneer the use of an AICI assistant that can be embedded within standard applications to support interactive decision-making for consumer businesses 24/7, and will leverage the OpenAI Large Language Model (LLM).
This new product adds generative AI capabilities to Market Logic's expertise in managing market and consumer insights within enterprise organisations. Rather than generating search results in a list, this technology will allow business users to receive complete, natural language answers to their market and consumer intelligence questions.
"This product will free up valuable resources for insights teams while simultaneously driving an insights-driven culture by providing trusted insights integrated directly into your daily workflows," said Olaf Lenzmann, Chief Innovation & Product Officer at Market Logic Software. "Ultimately, this means companies can make better decisions and deliver stronger ROI on their research. We're excited to be taking this next step into the world of AICI and to continue building better insights solutions with our clients and partners."
The announcement builds on Market Logic's long history of innovation within the insights industry. The company's award-winning insights engagement platform has helped clients such as Nike, L'Oréal, Mercedes-Benz, Phillips, and Unilever to centralize all internal and external knowledge assets, conduct new research, and connect with business stakeholders through a single hub.
Market Logic has already enlisted several Fortune 500 lead users in its limited beta program for the AICI assistant product. The company plans to launch the product globally later this year.
Get In Touch
For more information about Artificial Intelligence for Consumer Insights (AICI), please click here. For press enquiries and product release information, please contact [email protected].
About Market Logic
For more than 15 years, Market Logic has partnered with the world's most innovative companies to help activate their consumer and market insights. The company's end-to-end insights platform is a company-wide place where teams can inform, align, and grow their business. Serving a global client base, Market Logic works across verticals, enabling CPG, healthcare, retail, automotive, finance and telecoms organizations to access 600+ research agencies and 1000+ industry sources to create memorable, actionable insights at a fraction of the time and cost. Visit www.marketlogicsoftware.com to learn more.
Contact Information:
Caroline Woods
PR & Communications Manager
[email protected]
Press Release Service by Newswire.com
Original Source: Market Logic Software to Launch First Generative AI Solution for Consumer Insights
FDA Clears ‘Selux NGP System’ for Rapid Antibiotic Susceptibility Testing
BOSTON - January 19, 2023 - (Newswire.com)
Selux Diagnostics, a biotech startup in Boston whose mission is to combat superbug infections and antimicrobial resistance (AMR), announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Next Generation Phenotyping (NGP) System — a rapid antibiotic susceptibility (AST) testing platform that provides targeted therapeutic results days faster than the current standard of care.
The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel. Selux's NGP Gram-Negative panel is currently under review by the FDA.
"This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance. Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs. We thank all our employees, partners, and advisors who contributed to this tremendous accomplishment," said Steve Lufkin, CEO of Selux Diagnostics.
"We have been waiting for true innovation in AST technologies to deliver rapid results that are accurate according to the latest FDA guidelines and include newly approved antibiotics," said James S. Lewis II, PharmD, FIDSA, co-director of antibiotic stewardship at Oregon Health and Science University, and chair, CLSI Antimicrobial Susceptibility Testing Subcommittee. "I am enthusiastic that the Selux NGP System addresses these critical needs and will become an essential tool for directing personalized therapies for infected patients."
Experts predict that without a significant change in today's treatment options, deaths from superbugs will surpass deaths from cancer by 2050. Selux is confronting this global health crisis head-on by redefining the speed and performance of AST, the critical diagnostic test that informs personalized antibiotic therapy.
For more information on the Selux NGP System, visit www.seluxdx.com.
Acknowledgment
This platform has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); and Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.
About Selux Diagnostics
Selux Diagnostics is transforming patient care by accelerating the selection of personalized antimicrobial therapy for all Infectious Disease patients. This advance will save lives, shorten hospital stays, and combat the growing antibiotic resistance epidemic by decreasing the overuse of broad-spectrum agents. Learn more at www.seluxdx.com.
Contact Information:
Andrea LePain
[email protected]
617-894-1153
Press Release Service by Newswire.com
Original Source: FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing
Just Funky Named to Inc.’s 2022 Best in Business List for Second Time
BOCA RATON, Fla. - January 18, 2023 - (Newswire.com)
Just Funky, one of the top Licensed merchandise manufacturers, has been named to the Inc. 2022 Best in Business list in the General Excellence category. Inc.'s Best in Business awards honor companies that have made an extraordinary impact and influence in their fields, communities, the environment, and on society as a whole.
The list, which can be found in the Winter issue of Inc. magazine (on newsstands Dec. 13), recognizes the most dynamic companies of all sizes and industries that have had an outstanding influence on their communities or their industries.
"Just Funky is honored to be included in the Inc. Best in Business list," said Raj Arora, CEO, Just Funky.
Just Funky is growing at an unstoppable pace with more than 20,000 independent retail partners across North America and now the European Union. The company has more than 110 employees with offices in Columbus, Ohio, Los Angeles, Hong Kong, London, Boca Raton and New Delhi. Just Funky manufactured goods can be found at big-name retailers like Gamestop, Spencer's, Target, Hot Topic, and more.
"Inc. magazine is dedicated to showcasing America's most dynamic businesses and the great things they do," said Scott Omelianuk, Editor-in-Chief of Inc. "The Best in Business awards shine a light on those that have gone above and beyond their original mission to make a social, environmental or economic impact, benefiting those around them."
"I am so proud of our team's ability to innovate and provide our customers with the best products and service to help them demonstrate the value of quality and innovation to the consumers" said Pranav Arora, Head of Division of Just Funky.
About Just Funky
Just Funky is a global lifestyle company that is deliberately different, as it continues expanding with a growing presence in over 10,000 stores across the globe. It maintains partners with several global retailers, including Spencer's, Target, GameStop, Hot Topic, Box Lunch, and more, including e-commerce partnerships with Stunned Mind. Beyond that, Just Funky is rapidly becoming the established authority on everything pop-culture with a growing variety of products created for fans, by fans.
About Inc.
The world's most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community they need to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.
Alexa H
Just Funky
+1 234-249-0145
email us here
Visit us on social media:
Facebook
LinkedIn
Contact Information:
Alexa H
Marketing
[email protected]
2342490145
Related Images
Press Release Service by Newswire.com
Original Source: Just Funky Named to Inc.'s 2022 Best in Business List for Second Time